News
MRKR
1.570
-8.72%
-0.150
Weekly Report: what happened at MRKR last week (0210-0214)?
Weekly Report · 1d ago
Marker Therapeutics initiated with a Buy at Brookline
TipRanks · 02/10 23:05
Weekly Report: what happened at MRKR last week (0203-0207)?
Weekly Report · 02/10 11:03
Weekly Report: what happened at MRKR last week (0127-0131)?
Weekly Report · 02/03 11:08
Weekly Report: what happened at MRKR last week (0120-0124)?
Weekly Report · 01/27 11:10
Life sciences stocks fall on NIH funding concerns
Seeking Alpha · 01/23 17:55
Weekly Report: what happened at MRKR last week (0113-0117)?
Weekly Report · 01/20 11:02
Weekly Report: what happened at MRKR last week (0106-0110)?
Weekly Report · 01/13 11:03
Weekly Report: what happened at MRKR last week (1230-0103)?
Weekly Report · 01/06 11:11
Weekly Report: what happened at MRKR last week (1223-1227)?
Weekly Report · 12/30/2024 11:05
Weekly Report: what happened at MRKR last week (1216-1220)?
Weekly Report · 12/23/2024 11:11
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/20/2024 15:50
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 12/19/2024 21:06
BUZZ-U.S. STOCKS ON THE MOVE-Darden Restaurants, Natgas firms, Affirm Holdings
Reuters · 12/19/2024 18:41
Marker Therapeutics Reports Promising Results from Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma Patients
Barchart · 12/19/2024 17:24
Marker Therapeutics, Inc. Secures $16.1 Million in Private Placement to Advance MT-601 Clinical Study for Lymphoma Treatment
Barchart · 12/19/2024 17:24
Marker Therapeutics Updates APOLLO Study In Relapsed Lymphoma, Announces $16.1 Mln Private Placement
NASDAQ · 12/19/2024 16:25
BUZZ-Marker Therapeutics slides after $16 mln private placement
Reuters · 12/19/2024 13:29
Marker Therapeutics sells 5.03M shares at $3.20 in private placement
TipRanks · 12/19/2024 13:25
Marker Therapeutics provides update on MT-601 patients
TipRanks · 12/19/2024 13:10
More
Webull provides a variety of real-time MRKR stock news. You can receive the latest news about Marker Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.